Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Clearside Biomedical Inc.

Clearside Biomedical Inc ( ($CLSD) ) has released its Q3 earnings. Here is a breakdown of the information Clearside Biomedical Inc presented to its...

Clearside Biomedical Inc. Explores Strategic Alternatives

The Vanguard Total Stock Market ETF ($VTI) tracks the performance of the entire U.S. equity market. VTI ETF is down 1.88% over the past five days, ...

Current Quarter	$-0.67	Next Quarter	$-1.35
Current Year	$-4.8	Next Year	$-4.31
QoQ Growth	-101.5%	YoY Growth	+10.2%
3Y EPS CAGR	-265.9%	Target Price	$59.97
Consensus	Buy	Upside	+2104.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CLSD	$2.72	+4.21%	26.44K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CLSD	$2.72	+4.2%	26.44K
3
4
5
6

CLSD

CLSD

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Clearside Biomedical Inc. Data in Excel

Get Clearside Biomedical Inc. Data in Excel